Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
People in Britain Say Find Aliens, Cure Cancer
Author(s)OBTN
A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.
Advertisement
A recent poll conducted by Britain’s Royal Society found that what Britons want most is a vaccine that will prevent cancer, with nearly 80% of respondents selecting it as their top priority for science. Of the 2000 people surveyed, 60% picked HIV/AIDS prevention as their next choice. Although 44% expressed a belief in aliens and more than one-third think scientists should be trying to find and contact them, less than 10% identified space exploration as a top priority for science.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5